Pembrolizumab PK Fact Sheet

Details

Generic Name	Pembrolizumab
Trade Name	Keytruda®
Class	Antineoplastic agents, monoclonal antibody
Molecular Weight	~149 kDa

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity	Exposure increases in a dose-proportional manner within the dose range for efficacy.
Steady state	Achieved after 16 weeks of repeated dosing on an every 3-week regimen.
Plasma half-life	22 days.
Cmax	Not reported.
Cmin	22 µg/mL at a dose of 2 mg/kg every 3 weeks.
	29 µg/mL at a dose of 200 mg every 3 weeks.
AUC	794 µg·day/mL at a dose of 2 mg/kg every 3 weeks.
	1053 µg·day/mL at a dose of 200 mg every 3 weeks.
Bioavailability	Completely bioavailable.
Absorption	Administered IV.
Protein Binding	Does not bind to plasma proteins in a specific manner.
Volume of Distribution	~6 L.
CSF:Plasma ratio	Not determined.
Semen:Plasma ratio	Not determined.
Renal Clearance	Not reported.
Renal Impairment	No dose adjustment required for patients with mild to moderate renal impairment.
	Coadministration in patients with severe renal impairment has not been studied.
Hepatic Impairment	No dose adjustment required for patients with mild hepatic impairment.
	Coadministration in patients with moderate-severe hepatic impairment has not been studied.

Metabolism and Distribution

Metabolised by	Catabolised through non-specific pathways.
Inducer of	None reported.
Inhibitor of	None reported.
Transported by	None reported.

References

Unless otherwise stated (see below), information is from:

Keytruda SmPC, Merck Sharp & Dohme Ltd., August 2019.

Keytruda Prescribing Information, Merck & Co., Inc., September 2019.